ALLMedicine™ Chordoma Center

Feb 21st, 2021 - Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. We r...

Feb 20th, 2021 - The SWI/SNF complex core subunit SMARCB1 is inactivated in a variety of neoplasms that share characteristic "rhabdoid" cytomorphology. The aim of this study was to evaluate SMARCB1-deficient soft tissue neoplasms on cytology to identify diagnostic...

Feb 17th, 2021 - Brachyury is a transcription factor overexpressed in chordoma and is associated with chemotherapy resistance and epithelial-to-mesenchymal transition. GI-6301 is a recombinant, heat-killed Saccharomyces cerevisiae yeast-based vaccine targeting bra...

Feb 16th, 2021 - Chordoma is a notochord-derived primary tumor of the skull base and vertebral column known to affect 0.08 to 0.5 per 100,000 persons worldwide. Patients commonly present with mechanical, midline pain with or without radicular features secondary to...

Feb 16th, 2021 - Local reconstruction of central skull base defects may be inadequate for large defects or reoperative cases; free tissue transfer may be necessary. Inset of the flap and management of the pedicle can be challenging. We report our experience and ap...

Jan 31st, 2017 - The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's g.

Jun 7th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

Feb 21st, 2021 - Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. We r...

Feb 20th, 2021 - The SWI/SNF complex core subunit SMARCB1 is inactivated in a variety of neoplasms that share characteristic "rhabdoid" cytomorphology. The aim of this study was to evaluate SMARCB1-deficient soft tissue neoplasms on cytology to identify diagnostic...

Feb 17th, 2021 - Brachyury is a transcription factor overexpressed in chordoma and is associated with chemotherapy resistance and epithelial-to-mesenchymal transition. GI-6301 is a recombinant, heat-killed Saccharomyces cerevisiae yeast-based vaccine targeting bra...

Feb 16th, 2021 - Chordoma is a notochord-derived primary tumor of the skull base and vertebral column known to affect 0.08 to 0.5 per 100,000 persons worldwide. Patients commonly present with mechanical, midline pain with or without radicular features secondary to...

Feb 16th, 2021 - Local reconstruction of central skull base defects may be inadequate for large defects or reoperative cases; free tissue transfer may be necessary. Inset of the flap and management of the pedicle can be challenging. We report our experience and ap...

Apr 25th, 2018 - The drugmaker Epizyme has temporarily halted U. S.

Apr 25th, 2018 - The US Food and Drug Administration (FDA) has placed a partial hold on clinical trials of tazemetostat, an EZH2 inhibitor being developed to treat solid tumors and lymphomas. The hold has halted enrollment in US-based trials of tazemetostat, but s.

Oct 15th, 2015 - Jonathan C. Trent, MD, PhD Breelyn A. Wilky, MD Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process. ...

Apr 8th, 2015 - Patients with chordoma, caregivers, and health care professionals have a new resource to aid in their fight against chordoma, with the publication of the first detailed, multidisciplinary treatment guidelines in the journal The Lancet Oncology. Th.

Apr 8th, 2015 - Chordoma patients, caregivers, and health care professionals have a new resource to aid in their fight against chordoma, with the publication of the first detailed, multidisciplinary treatment guidelines in the journal The Lancet Oncology. These r.